New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:34 EDTCVMCEL-SCI reports 93% sequential enrollment increase in head and neck cancer trial
CEL-SCI announced that during the month of June the company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled. So far, a total of 218 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015. “As a result of active patient recruitment ongoing in an increasing number of clinical centers around the world, we are seeing the kind of acceleration we expect in patient enrollment numbers. With the United Kingdom having recently cleared our study, we are well past the halfway mark for country approvals. We are looking forward to receiving approvals from multiple additional countries later this year before being fully approved in all participating countries,” stated CEL-SCI CEO Geert Kersten.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:25 EDTCVMOn The Fly: Pre-market Movers
Subscribe for More Information
09:08 EDTCVMCEL-SCI prices $16M of common stock and warrants at 79c
Subscribe for More Information
08:29 EDTCVMFBR scuttled CEL-SCI offering after 'CEO meddling,' Feuerstein says
FBR scuttled its role in a CEL-SCI (CVM) offering due to "inappropriate CEO meddling," leaving Dawson James to be "brought on to salvage something," according to TheStreet's Adam Feuerstein citing a source. The Fly notes CEL-SCI announced last night a proposed offering of common stock and warrants, with no amount given and Dawson James Securities acting as the sole placement agent on a "best efforts" basis. IsoRay (ISR) tried to raise money yesterday too, Feuerstein reported on Twitter, citing an investor source.
May 21, 2015
18:49 EDTCVMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 1%. ALSO HIGHER: Autobytel (ABTL), up 14.1% after acquiring Dealix Corporation and Autotegrity from CDK Global (CDK) for $25M and raising fiscal 2015 guidance... StemCells (STEM), up 2.5% after being initiated with a Buy at Cantor... PTC Therapeutics (PTCT), up 2.3% after a Benefit Assessment by Germany's Federal Joint Committee indicated that Translarna provided a benefit for ambulatory patients... CBOE Holdings (CBOE), up 1.6% after raising share repurchase authorization by $100M... Cypress Semiconductor (CY), up 1.2% after being initiated with a Buy at Mizuho. DOWN AFTER EARNINGS: Aeropostale (ARO), down 18.5%... Brocade (BRCD), down 2.1%... Marvell Technology (MRVL), down 2.9% after reporting quarterly results and departure of CFO. ALSO LOWER: Otonomy (OTIC), down 17.7% following report of Phase 2b topline data for OTO-104... Viggle (VGGL), down 18.8% after filing to sell common stock... CEL-SCI (CVM),down 2.7% after announcing a proposed offering of common stock and warrants.
16:35 EDTCVMCEL-SCI announces proposed offering of common stock, warrants, no amount given
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use